AstraZeneca's Lynparza cancer drug approved by Japan

29th Dec 2020 07:02

(Sharecast News) - AstraZeneca and Merck's Lynparza has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers, the UK-based pharmaceutical company said on Tuesday.
The concurrent approvals by the Japanese Ministry of Health, Labour, and Welfare are based on positive results from the PAOLA-1, PROfound and POLO Phase III trials, which each were published in The New England Journal of Medicine.

Top Risers

Share	Price	Change
Westmount Engy. (WTE)	0.85	61.9%
Tiger Resource (TIR)	1.80	20%
Nativo Resources (NTVO)	0.375	15.38%
GEO Exploration Limited (GEO)	0.205	13.89%
Aoti, Inc. (AOTI)	65.00	13.04%

Top Fallers

Share	Price	Change
Alien Metals (UFO)	0.1175	-11.32%
Metir Plc (MET)	0.725	-11.04%
Metals One (MET1)	4.90	-10.91%
United Oil&gas (UOG)	0.155	-8.82%
Avacta Group (AVCT)	47.00	-8.74%

Top By Volume

Share	Price	Volume
Premier African Minerals (PREM)	0.028	604,907,321
Mirriad Advertising (MIRI)	0.012	486,777,636
Oracle Power (ORCP)	0.0165	344,129,232
Caledonian Hold (CHP)	0.003	324,117,386
Empyrean (EME)	0.11	305,748,767

All prices are delayed by at least 15 minutes. Share Compare cannot be held responsible for the accuracy of share prices shown on this website, and investors should be aware that share prices can go down as well as up. Share Compare does not offer advice, and is not regulated by the Financial Conduct Authority.